1999
Follow‐up recommendations for patients with American Joint Committee on Cancer Stages I–III malignant melanoma
Poo‐Hwu W, Ariyan S, Lamb L, Papac R, Zelterman D, Hu G, Brown J, Fischer D, Bolognia J, Buzaid A. Follow‐up recommendations for patients with American Joint Committee on Cancer Stages I–III malignant melanoma. Cancer 1999, 86: 2252-2258. PMID: 10590365, DOI: 10.1002/(sici)1097-0142(19991201)86:11<2252::aid-cncr12>3.0.co;2-q.Peer-Reviewed Original ResearchConceptsCancer stage IAmerican Joint CommitteePatient education programStage IYale Melanoma UnitSurveillance scheduleSymptomatic recurrenceMelanoma UnitSurveillance examinationsJoint CommitteeOverall survival rateStage of diseaseDetection of recurrenceAsymptomatic recurrenceAsymptomatic patientsDistant recurrenceLocoregional recurrenceHazard ratioDisease recurrenceInitial visitMore recurrencesMost recurrencesLate recurrenceMelanoma patientsRecurrence group
1997
Regional Isolated Perfusion of Extremities for Melanoma: A 20-Year Experience with Drugs Other than L-Phenylalanine Mustard
Ariyan S, Poo W, Bolognia J. Regional Isolated Perfusion of Extremities for Melanoma: A 20-Year Experience with Drugs Other than L-Phenylalanine Mustard. Plastic & Reconstructive Surgery 1997, 99: 1023-1029. PMID: 9091898, DOI: 10.1097/00006534-199704000-00016.Peer-Reviewed Original ResearchConceptsL-phenylalanine mustardRegional isolated perfusionIsolated limb perfusionIsolated perfusionLimb perfusionUpper extremityLower extremitiesTherapeutic isolated limb perfusionNonfatal pulmonary embolusRegional treatment modalityEvidence of diseaseHigh-dose chemotherapyHigh-risk melanomaNumber of patientsDifficult management problemDisease-free controlsTechnique of perfusionLimb recurrenceMeaningful palliationRepeat perfusionsAggressive treatmentPulmonary emboliDose chemotherapyRecurrent melanomaSerious complications